# Dolutegravir Impact on Residual Replication

> **NCT02500446** · PHASE4 · COMPLETED · sponsor: **University of Melbourne** · enrollment: 40 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** dolutegravir
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02500446
- **Lead sponsor:** University of Melbourne
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-28
- **Primary completion:** 2016-09-16
- **Final completion:** 2017-09-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-11-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02500446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02500446, "Dolutegravir Impact on Residual Replication". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02500446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*